2. Search Result
Search Result
Results for "

hemostasis

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131722
    EA4

    		Phospholipase Cardiovascular Disease
    EA4, a derivative of quinone, is an inhibitor for both rPLA and cPLA. EA4 can inhibit rPLA2 with a Ki value of 130 μM. EA4 can be used for the research of hemostasis, thrombosis, and erythropoiesis .
    EA4
  • HY-15827
    NSC 405020
    1 Publications Verification

    		 MMP Cardiovascular Disease Cancer
    NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 405020 reduces the expression of full length and active cleaved Notch3 (NICD3). NSC 405020 can be used to research vestibular schwannoma, hemostasis and thrombosis .
    NSC 405020
  • HY-N2138
    Buddlejasaponin IVb

    		Others Inflammation/Immunology
    Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .
    Buddlejasaponin IVb
  • HY-P9940
    Emicizumab

    		Factor VIII Cardiovascular Disease
    Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
    Emicizumab
  • HY-10563
    Sarpogrelate

    MCI-9042 free acid

    		 5-HT Receptor Infection
    Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT2 receptor antagonist, Sarpogrelate increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease .
    Sarpogrelate
  • HY-162363
    MD6a

    		PARP Neurological Disease
    MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect .
    MD6a
  • HY-B0149
    Tranexamic acid
    1 Publications Verification

    cyclocapron

    		 IGF-1R AMPK MMP Mitophagy Cardiovascular Disease Neurological Disease Cancer
    Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .
    Tranexamic acid
  • HY-D0199
    Adenosine 5'-diphosphate disodium

    		Endogenous Metabolite Cardiovascular Disease
    Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .
    Adenosine 5'-diphosphate disodium
  • HY-B1074
    Ethamsylate

    Etamsylate

    		 Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .
    Ethamsylate
  • HY-137431
    Asundexian

    BAY-2433334

    		 Factor Xa Cardiovascular Disease
    Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
    Asundexian
  • HY-B0149R
    Tranexamic acid (Standard)

    cyclocapron (Standard)

    		 IGF-1R AMPK MMP Mitophagy Cardiovascular Disease Neurological Disease Cancer
    Tranexamic acid (Standard) is the analytical standard of Tranexamic acid. This product is intended for research and analytical applications. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .
    Tranexamic acid (Standard)
  • HY-B1074R
    Ethamsylate (Standard)

    Etamsylate (Standard)

    		 Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Ethamsylate (Standard) is the analytical standard of Ethamsylate. This product is intended for research and analytical applications. Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .
    Ethamsylate (Standard)
  • HY-125856
    Milvexian

    BMS-986177; JNJ-70033093

    		 Factor Xa Cardiovascular Disease
    Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .
    Milvexian

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: